Hikma Pharmaceuticals’ (HIK) “Hold” Rating Reiterated at Peel Hunt

Peel Hunt restated their hold rating on shares of Hikma Pharmaceuticals (LON:HIK) in a report published on Monday morning, ThisIsMoney.Co.Uk reports.

Several other equities research analysts also recently weighed in on the company. Citigroup downgraded Hikma Pharmaceuticals to a neutral rating in a report on Monday, February 17th. Barclays restated an equal weight rating on shares of Hikma Pharmaceuticals in a research note on Thursday, February 20th. Morgan Stanley restated an equal weight rating on shares of Hikma Pharmaceuticals in a research note on Wednesday, November 13th. Jefferies Financial Group reduced their price objective on Hikma Pharmaceuticals from GBX 2,310 ($30.39) to GBX 2,240 ($29.47) and set a buy rating for the company in a research note on Tuesday, January 21st. Finally, HSBC restated a reduce rating on shares of Hikma Pharmaceuticals in a research note on Wednesday, November 27th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the stock. Hikma Pharmaceuticals presently has an average rating of Hold and a consensus target price of GBX 1,853.33 ($24.38).

Shares of LON HIK opened at GBX 1,809 ($23.80) on Monday. The company has a debt-to-equity ratio of 37.69, a quick ratio of 0.78 and a current ratio of 1.28. The company has a market cap of $4.42 billion and a PE ratio of 12.16. The business has a 50-day simple moving average of GBX 1,904.98 and a two-hundred day simple moving average of GBX 1,963.74. Hikma Pharmaceuticals has a fifty-two week low of GBX 16.58 ($0.22) and a fifty-two week high of GBX 2,089.19 ($27.48).

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals.

Further Reading: Differences Between Momentum Investing and Long Term Investing

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.